EPO and anemia (phenotype): In HF, factors such as increased levels of interleukin-6 and tumor necrosis factor-α that act by decreasing EPO production, decreasing the release of iron from the reticuloendothelial system, and decreasing iron absorption from the gut, along with the effects of ACE inhibitors on the hematopoietic system, lead to anemia [16].